NEFH and myeloid sarcoma: In another study, serum NfH levels were found to be 37 pg/mL in RRMS patients, 67 pg/mL in SPMS patients, and 72 pg/mLin PPMS patients indicating that NfH may be a useful biomarker for predicting the long-term course of the disease (Verberk et al., 2021); in addition, serum NfH level was associated with the number of T2 lesions and the duration of the disease, suggesting that serum-NfH may be useful as a biomarker of MS burden (Verberk et al., 2021).